WS Audiology (WSA), the Denmark-headquartered global hearing aid giant and parent company of renowned brands Widex, Signia, and Rexton, has affirmed its full-year fiscal year 2025/26 outlook, buoyed by a robust performance in its consumer-facing segments and significant improvements in profitability. Despite facing headwinds in its traditional wholesale business and adverse currency fluctuations, the company’s strengthened financial profile, marked by reduced debt and enhanced cash flow, has notably rekindled market speculation regarding a potential Initial Public Offering (IPO). The announcement, made on May 14, 2026, highlighted a strategic pivot towards direct-to-consumer channels and a relentless focus on operational efficiency as key drivers of its stable outlook.
Navigating a Dynamic Market: Q2 FY25/26 Performance Overview
For the second quarter of fiscal year 2025/26, ending March 31, 2026, WS Audiology reported a modest 1% organic revenue growth, reaching €628 million (approximately US$737 million). However, reported revenue saw a 6% decline, primarily attributed to unfavorable currency movements, particularly the weakening of the US dollar and Japanese yen against the euro. This mixed financial picture underscores the complex dynamics currently at play within the global hearing aid market.
The cornerstone of WSA’s Q2 performance was the exceptional growth within its consumer-facing business units. These segments—encompassing Online (including its prominent platform Hear.com), Managed Care (featuring TruHearing), and Retail (anchored by HearUSA)—collectively delivered an impressive 9% organic growth. The company noted that its Online channel continued its strong upward trajectory across various regions, reflecting a broader industry trend towards digital engagement and accessibility. Managed Care experienced a strong rebound, benefiting from an expanded base of covered lives and improved insurance benefits, while the Retail arm demonstrated solid growth, indicating sustained consumer demand for in-person services.
Conversely, WSA’s traditional Wholesale business experienced a 6% organic decline in the second quarter. The company attributed this contraction to two primary factors: a strategic implementation of stricter customer-base management aimed at enhancing overall profitability, and the timing of its product launches relative to those of key competitors. WSA indicated that the effects of this more stringent customer-base management are anticipated to largely conclude by the third quarter, suggesting a temporary impact rather than a long-term systemic issue. This strategic pruning of less profitable accounts, while impacting top-line wholesale figures in the short term, is a calculated move designed to optimize the business model for sustained financial health.
Geographical and Market Insights
From a geographical perspective, the Americas continued to be WSA’s strongest region, posting a robust 4% organic growth. This was primarily fueled by the strong performance of its Online and Managed Care segments in the United States, complemented by solid retail sales across the continent. In contrast, the EMEA (Europe, Middle East, and Africa) region experienced a 3% organic decline, where wholesale weakness partially offset the otherwise solid performance in retail and strong online results. The APAC (Asia-Pacific) region remained flat organically, as persistent softness in the critical Chinese market was balanced by stronger growth witnessed in Japan.
Industry-wide, global hearing aid unit growth was estimated at approximately 3% during the period, based on a combination of industry data and WSA’s internal assessments. However, the company cautioned that prevailing macroeconomic and political uncertainties continue to keep market growth below historical levels. Factors such as inflationary pressures, fluctuating interest rates, and broader geopolitical instability are creating a cautious environment for consumer spending on elective healthcare products, even those deemed essential for quality of life.
Profitability Surge and Debt Reduction
While revenue growth presented a mixed picture, profitability emerged as a significant highlight for WSA in the second quarter. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) before special items remained stable at €117 million (approximately US$137 million) compared to the prior year. More importantly, the EBITDA margin before special items saw a notable improvement, expanding by 1.1 percentage points to reach 18.6%. This margin expansion was attributed to a combination of factors, including a higher gross margin, reduced operating expenses, operational efficiencies achieved through ongoing initiatives, and structural cost reductions implemented during fiscal year 2024/25.
The company also returned to net profitability, reporting a quarterly profit of €16 million (US$19 million), a significant turnaround from a €10 million loss recorded in the same period last year. This return to the black was further supported by a substantial decline in net financial expenses, which fell to €52 million from €70 million a year earlier. This reduction was primarily driven by lower net interest expenses following a successful debt repricing and the repayment of PIK (Payment-In-Kind) notes in the previous financial year. Furthermore, operating cash flow saw a sharp improvement, soaring to €115 million from €55 million in the prior year, underscoring the company’s enhanced financial discipline and operational effectiveness.
)
For the first half of fiscal year 2025/26, WSA reported total revenue of €1.257 billion (approximately US$1.48 billion), with organic growth remaining flat. Reported revenue declined by 6%, again primarily due to adverse currency effects. EBITDA before special items for the half-year stood at €228 million, a marginal decrease from €231 million in the previous year, while the EBITDA margin improved to 18.1%, up 0.8 percentage points. These half-year figures reinforce the trend of improving profitability and financial health.
CEO’s Vision and Product Innovation
Jan Mäkelä, CEO of WSA, expressed cautious optimism regarding the company’s trajectory. In his statement on May 12, 2026, Mäkelä remarked, "Our organic revenue growth in the second quarter was in line with expectations, and we are continuously improving our profitability. It is encouraging that we are continuing to experience solid momentum in our Online and Retail channels, as well as strong performance in Managed Care. Today, we are launching the Signia Active Mini IX, the world’s smallest ready-to-wear hearing aid with the full power of the IX platform. We look forward to launching more breakthrough innovations on our Widex and Signia platforms soon."
This commentary highlights WSA’s dual strategy: leveraging the growth in consumer-facing channels while simultaneously driving innovation in its core product offerings. The launch of the Signia Active Mini IX exemplifies this commitment. Described as the world’s smallest ready-to-wear ITE (In-The-Ear) hearing aid, it combines advanced connectivity with the full capabilities of the IX platform. This device is strategically positioned as a discreet, rechargeable, and same-day fitting option that eliminates the need for custom molds, addressing a key consumer demand for convenience and immediate accessibility.
Beyond specific product launches, WSA also recently unveiled its "Sound Preference initiative." This builds upon compelling research indicating that up to 40% of listeners exhibit a strong, consistent preference for one sound-processing philosophy over another. By leveraging its two major technology platforms, Widex and Signia—each known for distinct sound processing characteristics—WSA believes it is uniquely positioned to apply this approach in highly personalized hearing care. This initiative underscores a deeper understanding of individual user needs and a commitment to tailoring solutions that optimize the user experience, potentially differentiating WSA in a competitive market. The company also confirmed that more products are in its innovation pipeline, with several expected to launch later in the current fiscal year.
The IPO Prospect: A Renewed Focus
)
WSA’s improved profitability and strengthening financial position have significantly renewed attention on its longer-term ownership path. As one of only two remaining privately held global hearing aid manufacturers—the other being US-based Starkey—WSA has long been considered a prime candidate for an IPO. Historically, high debt levels following its formation in 2019 from the merger of Sivantos and Widex, along with subsequent acquisitions, were seen as primary obstacles to a public listing. The company’s owners include global investment firm EQT and the Tøpholm and Westermann families, descendants of the founders of Widex.
The latest financial results, particularly the sharp decline in net financial expenses, lower net interest costs, and significant improvement in operating cash flow, strongly suggest that WSA is systematically addressing these previous concerns. Debt reduction has been a stated key step towards making a public listing more feasible and attractive to potential investors.
According to reports by MedWatch, EQT has already engaged leading financial institutions, including Danske Bank, Goldman Sachs, and Morgan Stanley, to prepare for a possible IPO on the Copenhagen stock exchange. While WSA has not commented on specific timing, CFO Marianne Wiinholt reiterated to MedWatch that any decision regarding an IPO ultimately rests with the company’s owners. Nevertheless, the continuous strengthening of its financial profile—marked by sustained profitability, reduced leverage, and robust cash generation—aligns perfectly with the rigorous scrutiny potential public-market investors would apply. A successful IPO would not only provide liquidity for existing shareholders but also grant WSA access to public capital markets for future growth and strategic investments.
Market Landscape and Strategic Positioning
WSA operates in a global market characterized by an aging population and a growing awareness of untreated hearing loss. The company is estimated to be the world’s third-largest hearing aid manufacturer, competing with industry giants like Sonova (Switzerland), Demant (Denmark), and GN Hearing (Denmark), alongside other key players. The competitive landscape is dynamic, driven by technological advancements, regulatory changes (such as the advent of Over-The-Counter or OTC hearing aids), and evolving consumer preferences.
A recent significant development in this context was the news, broken by HearingTracker, that WSA and Sony would no longer be partnering on Sony OTC hearing aids. This announcement, while marking the end of a high-profile collaboration, does not signal WSA’s withdrawal from the burgeoning OTC market. On the contrary, WSA has explicitly stated its continued intention to compete in the OTC hearing aid segment, underscoring its commitment to expanding accessibility to hearing care solutions. The experience gained from the Sony partnership, combined with its established retail and online channels, positions WSA to pursue its own strategy in this rapidly evolving market.
)
Outlook and Future Trajectory
Looking ahead, WSA has confidently maintained its full-year outlook for fiscal year 2025/26, projecting organic revenue growth in the range of 0-4%. This forecast is underpinned by the strength of its current product portfolio and the anticipated positive impact of upcoming product launches across its Widex and Signia platforms. Furthermore, the company expects its EBITDA margin before special items to improve by approximately 1 percentage point compared to fiscal year 2024/25. This projected margin expansion is expected to be driven by the sustained benefits of prior cost reduction initiatives, ongoing efficiency gains across its operations, and the anticipated positive leverage from revenue growth.
WS Audiology’s journey through a complex global market, marked by strategic shifts towards consumer-facing models and a tenacious focus on financial health, paints a picture of a company poised for a potentially transformative period. With a strong innovation pipeline and a clear path to improved profitability, the renewed buzz around a public listing positions WSA as a key entity to watch in the global healthcare and financial sectors.